Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
08/09/26	SEK 0.8990	+9.23%	2,544,746
04/09/26	SEK 0.8230	-3.18%	939,919
03/09/26	SEK 0.8500	-0.35%	666,382
02/09/26	SEK 0.8530	+5.57%	1,411,147
01/09/26	SEK 0.8080	+1.00%	707,328

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 02:00:00 08/09/26 am AEST			5-day change	1st Jan Change
0.8990 ^SEK	+9.23%		+12.38%	+8.44%

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	167M 17.39M 14.95M 14.07M 12.84M 24.01M 1.64B 24.09M 64.46M 842M 65.3M 63.88M 2.68B	P/E 2026 *	-3.05x	P/E 2027 *	-2.17x
Enterprise Value	151M 15.72M 13.52M 12.72M 11.61M 21.71M 1.49B 21.78M 58.28M 761M 59.04M 57.75M 2.43B	EV / Sales 2026 *	4.81x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
25/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
24/06	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
12/06	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
09/06	Alzinova raises SEK 15.2 million before issuance costs	FW
26/05	Calendar Tuesday May 26	FW
25/05	Calendar Tuesday May 26	FW
21/05	Alzinova secures 80 percent of TO4 warrants	FW

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
20/08	Alzinova publishes interim report for the period January - June 2026	AQ
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
25/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ

1 day	+9.23%
1 week	+12.38%
Current month	+12.38%
1 month	-15.51%
3 months	+95.43%
6 months	+58.00%
Current year	+8.44%

1 week	0.77	0.95
1 month	0.75	1.08
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+9.23%	+12.38%	-34.38%	-71.73%	17.43M
LONZA GROUP AG	-1.16%	-2.77%	-1.68%	+13.85%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+527.30%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+22.37%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+77.49%	40.73B
CELLTRION, INC.	-0.96%	-2.31%	+15.75%	+45.41%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+120.75%	16.5B
EUROFINS SCIENTIFIC SE	-1.54%	-1.30%	+12.02%	+31.14%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.12%	13.77B
Average	+0.06%	+0.23%	+61.68%	+89.74%	27.5B
Weighted average by Cap.	-0.95%	+0.05%	+89.17%	+128.65%

	2026 *	2027 *
Net sales	31.35M 3.27M 2.81M 2.64M 2.41M 4.51M 309M 4.53M 12.12M 158M 12.28M 12.01M 504M	-
Net income	-4.45M -464K -399K -375K -343K -641K -43.88M -643K -1.72M -22.47M -1.74M -1.7M -71.58M	-77M -8.03M -6.9M -6.49M -5.93M -11.09M -759M -11.12M -29.76M -389M -30.15M -29.49M -1.24B
Net Debt	-16M -1.67M -1.43M -1.35M -1.23M -2.3M -158M -2.31M -6.18M -80.8M -6.27M -6.13M -257M	-19M -1.98M -1.7M -1.6M -1.46M -2.74M -187M -2.74M -7.34M -95.95M -7.44M -7.28M -306M